NCT05376527 2026-04-21
Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact
"Oncostar" LLC
Phase 1 Completed
Clinical Trials
24 trialsNCT05281471 2026-03-18
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Phase 3 Recruiting
NCT06910657 2026-03-02
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Phase 1 Recruiting
NCT07006077 2026-02-27
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
Hangzhou Converd Co., Ltd.
Phase 2 Recruiting
NCT04725331 2025-11-21
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Phase 1/2 Terminated
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT07001592 2025-06-03
RIOT3
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT01443260 2025-04-30
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
Genelux Corporation
Phase 1/2 Completed
NCT00794131 2025-04-24
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
Genelux Corporation
Phase 1 Completed
NCT03954067 2025-04-22
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT02562755 2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3 Completed
NCT04022148 2019-07-19
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years
University of Fukui
Unknown
NCT01169584 2016-01-21
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Phase 1 Completed
NCT01171651 2016-01-20
A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
SillaJen, Inc.
Phase 2 Completed
NCT01380600 2016-01-08
Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1 Completed
NCT00574977 2015-12-28
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh
Phase 1 Completed
NCT00625456 2015-12-03
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
SillaJen, Inc.
Phase 1 Completed
NCT01584284 2015-08-25
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Genelux Corporation
Phase 1 Completed
NCT01387555 2015-03-11
TRAVERSE
Jennerex Biotherapeutics
Phase 2 Completed
NCT02017678 2014-09-17
Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
Mount Sinai Hospital, Canada
Phase 2 Withdrawn
NCT00629759 2013-01-04
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Jennerex Biotherapeutics
Phase 1 Completed
NCT00116597 2009-12-02
Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
University Hospital, Basel, Switzerland
Phase 1/2 Completed